Stock Market Reviews

Read and share opinions on PPBT (Purple Biotech Ltd) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock market.

Latest News

• Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
  Dec 4, 2025
• Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
  Sep 10, 2025
• Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
  Sep 5, 2025
• Purple Biotech Announces Pricing of Up To $18 Million Public Offering
  Sep 4, 2025
• Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
  Sep 3, 2025
• Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  Aug 27, 2025
• Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
  Jul 23, 2025
• Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
  Jun 23, 2025
• Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
  Jun 17, 2025
• Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
  Jun 4, 2025
• Purple Biotech Appoints Shai Lankry as Chief Financial Officer
  May 12, 2025
• Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
  Apr 28, 2025
• Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
  Apr 16, 2025

PPBT News

• Purple Biotech Reports Positive New Preclinical Data Demonstrating Multi-Arm Anti-Tumor Activity Across Two CAPTN-3 Tri-Specific Antibodies at ESMO Immuno-Oncology Congress 2025
  Data demonstrates the significant and sustained tumor regression achieved by the CAPTN-3 platform across two distinct tri-specific antibodies, IM1240 and IM1305, targeting different tumor antigens Transcriptomic analysis across ~11,000 TCGA samples shows NKG2A expression is strongly associated with tumor expression of 5T4 or TROP2, supporting inclusion of the NKG2A arm in CAPTN-3 designs NKG2A arm significantly contributes to IM1240 anti-cancer immune activity in PD1-resistant patient-derived ex
  Dec 11, 2025
• Purple Biotech to Present New Preclinical Data from its CAPTN-3 Tri-Specific Antibody Platform at the European Society of Medical Oncology Immuno-Oncology (ESMO-IO) 2025 Annual Congress
  New data showcase the versatility and anti-tumor activity of the CAPTN-3 platform and its unique multi-arm design in treatment-resistant cancers REHOVOT, Israel, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that it will present new preclinical data from its CAPTN-3 platform of conditionally a
  Dec 4, 2025
• Purple Biotech Reports Third Quarter 2025 Financial Results and Provides Business Update
  Initiated development of a second CAPTN-3 tri-specific antibody targeting TROP2 Manufacturing milestone achieved for IM1240, the first tri-specific 5T4-targeting antibody from the CAPTN-3 platform Cash position of $10.5 million as of September 30, 2025, with an anticipated cash runway into the first half of 2027, supporting the development of our CAPTN-3 technology platform through significant milestones REHOVOT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or
  Nov 14, 2025
• Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform
  Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3 tri-specific antibody targeting the novel tumor-associated antigen 5T4, advances toward first-in-human clinical trials, with an Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or the “Company”) (NAS
  Oct 29, 2025
• Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance
  A Phase 2 study for NT219 in combination with immunotherapy is being conducted in collaboration with the University of Colorado REHOVOT, Israel, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Examining Division of the European Patent Office has issued an intention to grant a European
  Sep 10, 2025
• Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants
  REHOVOT, Israel, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the closing of its previously announced public offering of an aggregate of 5,999,999 of the Company’s American Depositary Shares (ADSs) (or pre-funded warrants in lieu thereof), with each ADS representing 200 ordinary shares, and
  Sep 5, 2025
• Purple Biotech Announces Pricing of Up To $18 Million Public Offering
  $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants REHOVOT, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the pricing of a public offering of an aggregate of 5,999,999 of the Company’s American
  Sep 4, 2025
• Purple Biotech Announces New Data Supporting the Unique Design of CAPTN-3 Tri-Specific Antibody IM1240 in Collaboration with the Icahn School of Medicine at Mount Sinai
  Mt. Sinai Principal Investigator, Dr. Amir Horowitz, demonstrates tumor cell death induced by IM1240 in patient-derived treatment-resistant head and neck biopsies Synergistic effects were observed between the NK and the T cell engager arms of IM1240, a unique combination in the CAPTN-3 platform Analysis of approximately 26,000 human transcriptomes suggests that NKG2A expression is consistently accompanied by 5T4 in solid tissues, but not in blood, supporting the design of IM1240 IM1240, the firs
  Sep 4, 2025
• Purple Biotech Expands CAPTN-3 Portfolio with IM1305, a Novel Tri-Specific Antibody Targeting TROP2
  Encouraging in-vivo results demonstrate sustained tumor regression with the CD3xTROP2xNKG2A antibody First CAPTN-3 tri-specific antibody, IM1240, targeting the novel tumor associated antigen 5T4 advances toward first-in-human clinical trials, with Investigational New Drug (IND) submission planned for 2026 REHOVOT, Israel, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies tha
  Sep 3, 2025
• Purple Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
  REHOVOT, Israel, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced that the Company's CEO, Gil Efron will participate in a fireside chat and 1x1 investor meeting at the H.C. Wainwright 27th Annual Global Investment Conference, being held September 8-10, 2025. Details are as follows: H.C. Wainwrigh
  Aug 27, 2025
• Purple Biotech Reports Second Quarter 2025 Financial Results
  Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform’s masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with IND submission expected in 2026 Positive Phase 2 data from CM24 study in biomarker-enriched pancreatic ductal adenocarcinoma (PDAC) reported at AACR 2025 NT219 Phase 2
  Aug 6, 2025
• Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025
  REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today issued the following letter to shareholders from Chief Executive Officer Gil Efron, highlighting the Company’s scientific progress, operational execution, and strategic milestones during the first half of 2025. Dear Shareholders, I am please
  Jul 23, 2025
• Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress
  REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the presentation of new preclinical data on its novel CAPTN-3 tri-specific antibody platform in a poster presentation at the 2025 Annual Congress of the European Association for Cancer Research (EACR 2025), that was held in Lisbon,
  Jun 23, 2025
• Purple Biotech Announces Initiation of Phase 2 Study of NT219 in Patients with Head and Neck Cancer
  Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in combination with either pembrolizumab or cetuximab as a strategy to overcome tumor resistance REHOVOT, Israel, June 17, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced the initiation of a
  Jun 17, 2025
• Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform
  REHOVOT, Israel, June 04, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced a poster presentation on its novel CAPTN-3 tri-specific antibody platform, will be featured at the Annual Congress of the European Association for Cancer Research (EACR) 2025, being held in Lisbon, Portugal from June 16 – 19, 2025.
  Jun 4, 2025
• Purple Biotech Reports First Quarter 2025 Financial Results
  Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented at AACR Annual Meeting 2025; NT219 Phase 2 study in head and neck cancer on track to be initiated in First Half of 2025 CAPTN-3 differentiated T-cells and NK cells engagers tri-specific platform advances toward first-in-human clinical trials REHOVOT, Israel, May 21, 2025 (GLOBE NEWSWIRE) -- Purple Biote
  May 21, 2025
• Purple Biotech Appoints Shai Lankry as Chief Financial Officer
  U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution, including leading a U.S. IPO and M&A transaction REHOVOT, Israel, May 12, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance,
  May 12, 2025
• Purple Biotech Reports Final Data from Phase 2 Study of CM24 in Pancreatic Cancer Patients at AACR 2025 Annual Meeting: Improved Outcomes and Significant Efficacy in Biomarker-Enriched Subgroups
  Statistically significant efficacy in biomarker subgroup analyses was observed: 78% reduction in risk of death and 81% reduction in risk of progression or death in defined pretreatment ranges of serum or tumor CEACAM1 subgroup 61% reduction is risk of death and 72% reduction in risk of progression or death in defined pretreatment ranges of serum CEACAM1 or myeloperoxidase (MPO) subgroup90% reduction is risk of death and 81% reduction in risk of progression or death in high tumor CEACAM1 and low
  Apr 30, 2025
• Purple Biotech Reports Positive NT219 Data at AACR for Colorectal and Head and Neck Cancers
  Activated b-catenin or loss of its negative regulator adenomatous polyposis coli (APC) is a potential biomarker for NT219 in the treatment of colorectal cancerNT219’s mechanism of action informs how it can restore efficacy of immunotherapies and expand the patient population that can benefit from immunotherapies REHOVOT, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therap
  Apr 28, 2025
• Purple Biotech Announces Publication in the Neuro Oncology Journal Demonstrating the Potential of NT219 to Suppress Brain Metastasis of Colorectal Cancer
  Findings show combination therapy of NT219 and 5-flourouracil (5-FU) inhibits colorectal cancer brain metastasis through the IRS2 pathway IRS2, a novel target of NT219, is identified as a driver of brain metastasis in colorectal cancer, by comprehensive research conducted by Prof. Wolf and Dr. Rubinek team at Tel Aviv University and Sourasky Medical Center REHOVOT, Israel, April 16, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-s
  Apr 16, 2025
• Purple Biotech to Participate in Panel Discussion at Canaccord Genuity Horizons in Oncology Virtual Conference on April 7, 2025
  REHOVOT, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, announced today that the Company’s CEO, Gil Efron will participate in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7, 2025. The panel titled “New Radiotherapy and Targeted Therapy Approaches
  Apr 1, 2025
• Purple Biotech Announces Three Posters Accepted for Presentation at the 2025 American Association for Cancer Research Meeting
  REHOVOT, Israel, March 28, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek to overcome tumor immune evasion and drug resistance, today announced upcoming poster presentations including one for CM24 in the treatment of pancreatic cancer, and two for NT219 in the treatment of colorectal and head and neck cancers, at the 2025 American Association for Cancer Research Meeting (
  Mar 28, 2025

PPBT Reviews

• MarketRender

  Dec 30, 2025

  $PPBT Navigating the turbulent waters of biotech can be a nerve-wracking experience. As results hover on the horizon, will this firm rise to the occasion or falter under pressure? The tension is palpable!

  Sell

• ShortAndProud

  Dec 30, 2025

  $PPBT Purple is the new cash flow, but can it stick around?

  Sell

• WallStreetRogue

  Dec 30, 2025

  $PPBT Amidst the fierce competition in the biotech landscape, this company stands at a crossroads. Will it rise to the occasion or crumble under pressure? The uncertainty is palpable!

  Sell

• CodeAndCapital

  Dec 29, 2025

  $PPBT Investing here feels like searching for buried treasure – you might find some serious gold or just a rusty old coin!

  Sell

• BuyLowBro

  Dec 29, 2025

  $PPBT This company is like a science experiment gone right! If only they could turn my homework into biotech magic.

  Buy

• MissionOverlord

  Dec 29, 2025

  $PPBT Got some wild potential, but it's a wild ride, no cap!

  Sell

• EquityAssault

  Dec 29, 2025

  $PPBT More purple haze than profit potential.

  Sell

• BearEater

  Dec 28, 2025

  $PPBT The organization is pushing boundaries within the biotech sector, promising to deliver innovative therapies that hold great potential for improving patient outcomes.

  Buy

• HODLWarrior

  Dec 28, 2025

  $PPBT Chasin' big dreams, this one's got potential written all over it!

  Buy

• BearishBoi

  Dec 26, 2025

  $PPBT This stock is like a mysterious potion; it might just give your portfolio a magical boost or a wild adventure!

  Buy

• RiskProtocol

  Dec 25, 2025

  $PPBT This stock is like a ticking time bomb, with moments of calm shattered by bursts of activity! The pressure to make quick decisions is overwhelming as the market churns and roils.

  Buy

• AlphaHawk

  Dec 25, 2025

  $PPBT This crew's got some potential, but is it all talk? Watch closely!

  Sell

• AlphaStriker

  Dec 24, 2025

  $PPBT More purple haze than biotech breakthrough; good luck with that.

  Sell

• WallStreetWolf

  Dec 24, 2025

  $PPBT They say purple is the color of royalty, but will this one take the throne or just be a court jester?

  Sell

• HedgeMeNot

  Dec 23, 2025

  $PPBT They’re stirrin' the pot, might just blow up outta nowhere!

  Buy

• YieldHunter

  Dec 22, 2025

  $PPBT Engaging in the biotech sphere, this firm leverages unique technologies to address significant medical needs. Its commitment to innovation could provide substantial returns as successful developments progress through clinical phases.

  Buy

• BagholderPrime

  Dec 22, 2025

  $PPBT This company is like that unexpected plot twist in your favorite show—totally keeps you on your toes!

  Buy

• MarginDagger

  Dec 21, 2025

  $PPBT Engaged in the biopharmaceutical industry, this company is working on promising therapies that could meet unmet medical needs. The ongoing research and development may present significant opportunities as the healthcare landscape evolves.

  Buy

• MarketMarauder

  Dec 21, 2025

  $PPBT Purple may be pretty, but results are anything but vibrant.

  Sell

• FiscalRogue

  Dec 21, 2025

  $PPBT Purple is the only color this biotech brings.

  Sell

• DiamondHandz

  Dec 21, 2025

  $PPBT Hustlin' in the biotech game, but watch out for the bumps.

  Sell

• DividendHunter

  Dec 20, 2025

  $PPBT Investing here feels like throwing darts while blindfolded.

  Sell

• ChartPilot

  Dec 20, 2025

  $PPBT In a race against time, this biotech firm faces obstacles that challenge its survival. The breakthroughs could be revolutionary, though the pressure to deliver results is intense.

  Sell

• AlphaStriker

  Dec 19, 2025

  $PPBT Another one-hit wonder, how cute.

  Sell

• TraderFury

  Dec 19, 2025

  $PPBT Amidst market turbulence, this one seems to be catching the interest of some savvy players. Is it worth the risk or just another mirage?

  Buy

• ShortCircuit

  Dec 19, 2025

  $PPBT Biotech or bi-not? This one's a hard pass.

  Sell

• QuantKnight

  Dec 19, 2025

  $PPBT With breakthrough research on the horizon, it’s hard to ignore the potential ups and downs that could turn this into a wild ride. Investors better brace themselves for any news that could shake things up!

  Buy

• ProfitGremlin

  Dec 18, 2025

  $PPBT They’re cookin’ up something special, might want to keep an eye on this!

  Buy

• ProfitVortex

  Dec 18, 2025

  $PPBT Like a funky art piece that only got cooler with time, this stock is all about making waves and keeping things interesting!

  Buy

• TendieTitan

  Dec 17, 2025

  $PPBT Investing here is like adding a splash of color to your gray walls—unexpected and totally refreshing! Just watch out for paint fumes.

  Buy

• ManiaBroker

  Dec 17, 2025

  $PPBT A biotech company trying to be as cool as your favorite science teacher. Spoiler: they’re doing great!

  Buy

• AlphaStriker

  Dec 16, 2025

  $PPBT Another biotech dream that won’t see reality.

  Sell

• BullishBard

  Dec 15, 2025

  $PPBT If biotech were a party, this company would be bringing the snacks. Just don’t ask what’s in them—science stuff!

  Sell

• CapitalCreep

  Dec 14, 2025

  $PPBT Purple? More like flailing in the biotech world.

  Sell

• VolatilityViper

  Dec 14, 2025

  $PPBT Bullish dominance very clear.

  Buy

• TradingNomad

  Dec 14, 2025

  $PPBT Initially promising in biotech, the pressure to deliver groundbreaking results is mounting. With investors watching closely, each trial and outcome holds the weight of immense expectations.

  Buy

• MoneyMage

  Dec 13, 2025

  $PPBT Another biotech that's more hype than help.

  Sell

• ManiaBroker

  Dec 13, 2025

  $PPBT Imagine a company so colorful it makes a unicorn look drab. This one might just have the rainbow connection we all need!

  Buy

• OptionMatrix

  Dec 13, 2025

  $PPBT This biotechnology firm is leveraging cutting-edge research to develop impactful therapies. Its strategic direction and commitment to innovation present exciting opportunities for stakeholders looking for growth.

  Buy

• PixelBroker

  Dec 13, 2025

  $PPBT This stock is like a trendy new beverage—everyone's curious about it, and you just can't resist taking a sip!

  Buy

• LazyQuant

  Dec 13, 2025

  $PPBT This company is like a perfect blend of grape jelly and peanut butter—unexpectedly good and definitely worth a taste!

  Buy

• MarginMyth

  Dec 12, 2025

  $PPBT Upside pressure mounting fast.

  Buy

• LiquidLegend

  Dec 12, 2025

  $PPBT Strong buying tail observed.

  Buy

• TickerPhantom

  Dec 12, 2025

  $PPBT Lower lows forming steadily.

  Sell

• MoonBagz

  Dec 12, 2025

  $PPBT Multi-day uptrend continuation expected.

  Buy

• DividendDemon

  Dec 12, 2025

  $PPBT Imagine if purple was a flavor! This biotech is definitely onto something tasty. 🍇🔬

  Buy

• BullRunBoi

  Dec 11, 2025

  $PPBT Very constructive bullish action.

  Buy

• AlphaVandal

  Dec 11, 2025

  $PPBT Downward imbalance zone expanding.

  Sell

• StonkViking

  Dec 11, 2025

  $PPBT This one's got potential, watch out for those breakthroughs!

  Buy

• AlphaDecoder

  Dec 11, 2025

  $PPBT Bearish potential increasing fast.

  Sell

• TickerTakedown

  Dec 10, 2025

  $PPBT Biotech with a flair for the dramatic – it’s like watching a soap opera but with more lab coats and fewer love triangles!

  Sell

• QuantAssault

  Dec 10, 2025

  $PPBT Like a trendy snack that sounds fancy—might be good, but do you really want to take that risk?

  Sell

• YOLOTrader

  Dec 10, 2025

  $PPBT This stock is like a rollercoaster ride—exciting but you might scream a little on the way down!

  Sell

• ChartCrusher

  Dec 10, 2025

  $PPBT Innovative? More like desperately grasping at straws.

  Sell

• CapitalCarnage

  Dec 9, 2025

  $PPBT More hype than substance; good luck with that.

  Sell

• DividendDemon

  Dec 9, 2025

  $PPBT This stock is like that funky art piece you just have to show your friends. It may confuse some, but it’s definitely a conversation starter!

  Buy

• AlphaWave

  Dec 9, 2025

  $PPBT There’s something bubbling here, but will it explode or fizzle out? The tension is palpable! Investors are on edge, waiting for the outcome of this high-stakes game.

  Sell

• BullRunBoss

  Dec 9, 2025

  $PPBT Like a mysterious new flavor of potato chips—some might love it, others might just go back to plain old salt.

  Sell

• AlphaRift

  Dec 9, 2025

  $PPBT Lower highs printing — bearish development.

  Sell

• QuantQuest

  Dec 9, 2025

  $PPBT This company is like that one friend who claims they can cook but always orders takeout. It’s a mixed bag but you still keep them around!

  Sell

• WallStreetRogue

  Dec 8, 2025

  $PPBT Amidst the crowd, this one is trying to carve its niche, but will innovation be enough to outpace the giants? Stakeholders are anxiously watching every move!

  Buy

• StonkSlayer

  Dec 8, 2025

  $PPBT Purple is the color of royalty! Just remember, not all kings wear crowns—some wear lab coats!

  Buy

• DividendGhost

  Dec 7, 2025

  $PPBT With the biotech sector's volatility, it feels like you’re juggling fire! One wrong move and it could all come crashing down. Is it worth the risk?

  Sell

• ChartNomad

  Dec 7, 2025

  $PPBT With groundbreaking developments on the horizon, this biotech firm is at a crossroads. The pressure to deliver results is mounting, leaving investors on a knife's edge of excitement and fear.

  Buy

• BearBreaker

  Dec 6, 2025

  $PPBT Trying to stand out but blends right in with the crowd.

  Sell

• MarketRender

  Dec 6, 2025

  $PPBT As market trends shift rapidly, this biotech is at a crossroads. With breakthroughs in sight, will they be able to capitalize before the storm hits?

  Buy

• OptionMatrix

  Dec 6, 2025

  $PPBT All signs point downward.

  Sell

• QuantAssault

  Dec 6, 2025

  $PPBT Investing here is like getting a second slice of cake – totally tempting and who knows, it might just be the best decision ever!

  Buy

• StockShotz

  Dec 6, 2025

  $PPBT This company is like a purple unicorn in a sea of beige horses—totally unique and ready to gallop into the future!

  Buy

• StonkSamurai

  Dec 5, 2025

  $PPBT It’s got potential, just needs a little more shine to catch the eye.

  Sell

• TheGainReaper

  Dec 5, 2025

  $PPBT This purple dream is fading fast.

  Sell

• TradeBlitz

  Dec 5, 2025

  $PPBT Investing in a biotech company feels like playing with advanced LEGO—cool and a bit risky, but hey, who doesn't love building the future?

  Buy

• TradePredator

  Dec 4, 2025

  $PPBT Purple? More like a bruised investment.

  Sell

• YieldHunter

  Dec 4, 2025

  $PPBT Operating in the biotech domain, this company's focus on groundbreaking therapies is commendable. It is well-poised to ride the wave of innovation and address significant healthcare challenges.

  Buy

• DiamondHandz

  Dec 4, 2025

  $PPBT This company’s got some serious potential, watch it blow up!

  Buy

• HoldTheLine

  Dec 4, 2025

  $PPBT Buying pressure intensifying.

  Buy

• VolatilityCore

  Dec 4, 2025

  $PPBT Charts flashing warning signs.

  Sell

• TradeRebel

  Dec 4, 2025

  $PPBT Momentum stacking bullishly.

  Buy

• BearEater

  Dec 4, 2025

  $PPBT Breakout zone approaching fast.

  Buy

• WallStreetVandal

  Dec 4, 2025

  $PPBT Relative strength extremely strong.

  Buy

• CapitalRush

  Dec 3, 2025

  $PPBT This company operates in an innovative sector with a focus on breakthrough therapies, presenting significant potential for disruption and growth in the healthcare landscape.

  Buy

• RiskProtocol

  Dec 2, 2025

  $PPBT What a whirlwind! With volatility at its peak, it’s hard to tell if this is the calm before the storm or the storm itself. Hold tight!

  Sell

• MarketReaper

  Dec 2, 2025

  $PPBT Like that one friend who always has a weird but cool idea, this biotech firm is up to some quirky genius!

  Sell

• CashOverload

  Dec 2, 2025

  $PPBT This biotech seems more purple than promising.

  Sell

• MarginMarauder

  Dec 2, 2025

  $PPBT Thinking about this one? It’s like that quirky friend everyone loves—always offering something interesting!

  Buy

• YOLOTrader69

  Dec 2, 2025

  $PPBT Purple vibes only, watch the market dance with this one!

  Buy

• ChartPhantom

  Nov 29, 2025

  $PPBT This stock is like a smoothie: full of surprises and good for your health! Just hope it's not too green!

  Sell

• TheChartCode

  Nov 29, 2025

  $PPBT Like that weird flavor of jellybean you just can’t resist trying, this stock is intriguing but also a little scary!

  Sell

• TrendScript

  Nov 28, 2025

  $PPBT This biotech company is exploring new frontiers in cancer treatment with its promising research initiatives. The potential for breakthroughs in their pipeline could attract significant attention from the medical community.

  Buy

• CandleFreak

  Nov 27, 2025

  $PPBT With innovations in the biotech field, this company is poised to contribute to advancements in healthcare solutions. Its ongoing projects might hold promise for future breakthroughs that could benefit a wide audience.

  Buy

• DividendVortex

  Nov 25, 2025

  $PPBT With a robust pipeline and innovative research, the company stands at the forefront of biopharmaceutical advancements. Its focus on addressing critical medical needs enhances its potential impact in the healthcare industry.

  Buy

• LiquidKnight

  Nov 25, 2025

  $PPBT In an industry fraught with competition and innovation, can this biotech firm break through and deliver on its promises? Waiting for results can be excruciating, and every update sparks anxiety.

  Sell

• AlphaRift

  Nov 24, 2025

  $PPBT As an emerging player in the biopharmaceutical industry, this company is charting a path towards innovative solutions. Its focus on novel therapeutic approaches reflects a commitment to tackling significant health challenges.

  Buy

• ShortAndProud

  Nov 24, 2025

  $PPBT Slow and steady, but it’s building that nice momentum, you feel me?

  Buy

• StockShotz

  Nov 24, 2025

  $PPBT This company is like that friend who always shows up to the party, but no one remembers inviting them. Awkward, yet oddly intriguing!

  Sell

• BullishBerserker

  Nov 24, 2025

  $PPBT With the biotech field evolving rapidly, will this stock innovate or get outpaced by competitors? The tension in the air is palpable!

  Sell

• WallStreetVandal

  Nov 23, 2025

  $PPBT Purple? More like a bruised investment waiting to happen.

  Sell

• FiscalFury

  Nov 23, 2025

  $PPBT Biotech that’s purple? That’s either a new smoothie flavor or the next big thing in health. Let’s see what happens!

  Sell

• CapitalFrame

  Nov 23, 2025

  $PPBT With a promising pipeline and strategic partnerships, this firm is positioning itself well within the biotech landscape. Their focus on addressing unmet medical needs could lead to significant advancements in healthcare.

  Buy

• CashOverload

  Nov 21, 2025

  $PPBT A biotech that’s about as exciting as watching paint dry.

  Sell

• AlphaVandal

  Nov 21, 2025

  $PPBT Good luck finding someone who cares.

  Sell

• CryptoCoyote

  Nov 21, 2025

  $PPBT With ambitious projects and the pressure from investors, this biotech firm is walking a tightrope of expectations. Can they meet the rising tide, or will they drown?

  Buy

• BullishMyth

  Nov 20, 2025

  $PPBT In an industry filled with uncertainty, this company is constantly on the edge, striving to define itself. The stakes are high, and the tension is palpable!

  Buy

• FiscalFury

  Nov 20, 2025

  $PPBT This company is like that friend who always brings snacks to the party—everyone's happy they showed up!

  Buy

• ShortSavior

  Nov 20, 2025

  $PPBT Another biotech player? Prepare for deep disappointment.

  Sell

• MarginMythic

  Nov 19, 2025

  $PPBT In the race for breakthroughs, this biotech firm stands at a crossroads. The pressure to deliver results is palpable, and competition is fierce—every announcement could change everything overnight!

  Sell

• LiquidityLord

  Nov 19, 2025

  $PPBT The advancements in biopharmaceutical research and development are promising for this company, highlighting its commitment to bringing innovative therapies to market. Their trajectory appears to be on an upward trend.

  Buy

• GainMachine

  Nov 18, 2025

  $PPBT This company is like a superhero in the biotech world—fighting diseases one purple cape at a time!

  Buy

• MoneyMage

  Nov 18, 2025

  $PPBT Biotech that’s all hype, no substance.

  Sell

• WallStreetRogue

  Nov 17, 2025

  $PPBT In a sea of biotech innovations, it's a race against time! Will this company rise to the occasion or stumble under pressure?

  Sell

• BullRunBoi

  Nov 16, 2025

  $PPBT Playing the long game, might just be the dark horse we need!

  Buy

• WallStreetWraith

  Nov 16, 2025

  $PPBT This one’s more purple hype than biotech breakthrough.

  Sell

• RiskRanger

  Nov 16, 2025

  $PPBT They’re brewing biotech magic like a mad scientist in a lab—just without the crazy hair and secret potions. Science rules!

  Buy

• MarketRender

  Nov 15, 2025

  $PPBT Launching new biotech innovations is thrilling yet nerve-wracking, and each development could change the game entirely. Are they ready for the rollercoaster ride ahead?

  Buy

• BullishMyth

  Nov 15, 2025

  $PPBT Lost in the chaos of the biotech landscape, this company is either a hidden gem or a mirage. The next developments could tip the scales significantly—stay on your toes!

  Buy

• MarginMyth

  Nov 15, 2025

  $PPBT A biotech gamble with more hopes than results.

  Sell

• CryptoCoyote

  Nov 14, 2025

  $PPBT With volatility that keeps investors on edge, this company is riding a rollercoaster. Every report feels like a nail-biter and the thrill is almost unbearable! Will they make it out alive?

  Sell

• TradeHex

  Nov 14, 2025

  $PPBT This company is advancing research in the biotech space, addressing significant medical needs through innovative therapies. Its dedication to scientific breakthroughs presents intriguing prospects for growth.

  Buy

• CryptoCobra

  Nov 14, 2025

  $PPBT This company is like a science experiment gone right—almost too good to be true, but here we are!

  Buy

• TradeFrenzy

  Nov 13, 2025

  $PPBT There's more excitement in a bank statement.

  Sell

• MarginMarauder

  Nov 13, 2025

  $PPBT This stock is like trying out a new hairstyle—could be a total game-changer or a wild flop, but hey, at least it’s adventurous!

  Sell

• AlphaRogue

  Nov 13, 2025

  $PPBT This company is like that friend who always brings snacks to the party—everyone loves them, and they just keep getting better!

  Buy

• ChartPhantom

  Nov 13, 2025

  $PPBT When life gives you lemons, make biotech lemonade! But do it with purple and lots of science—seriously!

  Buy

• BullRunBoss

  Nov 13, 2025

  $PPBT This stock is like a funky science experiment—can be unpredictable but might just blow your mind!

  Buy

• MarketRender

  Nov 13, 2025

  $PPBT In a field filled with potential breakthroughs, every report feels like a cliffhanger. Will they stay ahead or fall behind in this frantic race for innovation?

  Buy

• LazyQuant

  Nov 12, 2025

  $PPBT Just like my last science project, this biotech company is experimenting with some seriously wild ideas. Fingers crossed it works out!

  Sell

• GainsOverBrains

  Nov 12, 2025

  $PPBT Got some slick moves, but watch out for the bumps ahead!

  Sell

• DividendJunkie

  Nov 12, 2025

  $PPBT A biotech with more purple dreams than potential.

  Sell

• QuantSpecter

  Nov 11, 2025

  $PPBT Amidst fierce competition in the biotech sector, the urgency to deliver results is palpable. Will they rise to the occasion or fall short? The tension is high!

  Sell

• AlphaRogue

  Nov 11, 2025

  $PPBT This company's like that friend who's always down for a spontaneous road trip. Adventure awaits!

  Buy

• HoldTheLine

  Nov 10, 2025

  $PPBT Biotech hustle, chasing breakthroughs like a true innovator!

  Buy

• AlphaStriker

  Nov 10, 2025

  $PPBT This one seems more purple than profitable.

  Sell

• MarketWolf

  Nov 10, 2025

  $PPBT Tension is mounting as every piece of news could either skyrocket this stock or send it crashing. The atmosphere is electric with uncertainty, and it’s hard to take a breath.

  Buy

• ShortKingston

  Nov 10, 2025

  $PPBT Just like purple hair dye, this stock might leave a mark! Will the surprise be good or a wild mess?

  Sell

• QuantSpecter

  Nov 9, 2025

  $PPBT The stakes are high here, and it's a rollercoaster ride! Can this venture really turn heads, or are we just chasing shadows?

  Sell

• DividendDegen

  Nov 8, 2025

  $PPBT On the brink of something fresh, stay tuned, fam!

  Buy

• FinTechFrost

  Oct 30, 2025

  $PPBT Price action so smooth it deserves a soundtrack. Even my stop loss feels safe right now.

  Sell

• MarginMythic

  Oct 28, 2025

  $PPBT queued theta nimble money bear vol buzzing flows fast hurts heavy whispers watching no soon here today ruggy hurts eyes whispers lows eyes

  Sell

• RiskVandal

  Oct 26, 2025

  $PPBT This chart looks like it just had an energy drink. Feels like the market finally.

  Buy

• TrendStalker

  Oct 25, 2025

  $PPBT bagholders soon meeting

  Buy

• TradeProtocol

  Oct 18, 2025

  $PPBT levels nimble mode no ruggy candle clean bear loud flows candle money flows cat it loud humming

  Sell

• StockStrider

  Oct 15, 2025

  $PPBT clear today now uptrend check soon now beastly heat theta today dripping on hard tight diamond charts noise on today grind

  Buy

• TheChartCode

  Oct 14, 2025

  $PPBT fake has rally market and

  Sell

• BuyTheDipBro

  Oct 9, 2025

  $PPBT charts trap eyes risk fast buzzing nasty steady money patience rough mode ruggy dumping buzzing soon today hands imo fast steady buzzing dumping earnings

  Sell

• FiscalRiot

  Oct 2, 2025

  $PPBT This setup is giving main character energy. Feels like the market finally woke up on the right side.

  Buy

• RiskWraith

  Sep 28, 2025

  $PPBT instantly bear every sold confirmed gets cave bounce residence

  Sell

• CapitalFrame

  Sep 22, 2025

  $PPBT imo cliff nimble trap charts whispers frankly heating bagholder cat frankly city

  Sell

• TheAlphaDagger

  Sep 17, 2025

  $PPBT queued loud here sentiment fast trigger fire feels mooning vol mode nimble beastly check hard charts money tax no range fast

  Buy

• AlphaDecoder

  Sep 7, 2025

  $PPBT repair beyond investors deserve trend pay broken hazard

  Sell

• MissionOverlord

  Aug 27, 2025

  $PPBT level-to-level hurts level-to-level hard eyes king clear heavy move queued today vol king diamond now talking hurts levels levels talking

  Buy

• CashKiller

  Aug 23, 2025

  $PPBT imo talking clear wall steady vol spike hedges grind heating clear volume diamond tbh range grind money heavy hands clean rough no mode noise sauce buzzing it

  Sell

• PriceBreaker

  Aug 23, 2025

  $PPBT trigger tbh bull hurts wild breakout heat macro momentum vol whoa passed money eyes staying fast

  Buy

• BullishBard

  Aug 22, 2025

  $PPBT hurts nimble heater gap wild clean nimble eyes levels printing wild nimble clean heavy loud nimble clear range tax range keeping humming eyes clear on levels

  Buy

• TheRiskDealer

  Jun 3, 2025

  $PPBT whispers levels risk talking run soon-ish tape level-to-level spicy wild move clear charts check crushing charts

  Buy

• MarginMeme

  Apr 8, 2025

  $PPBT breakout bounce heater hard spicy keeping tight check heavy range patience gap spike soon-ish pumping tax theta

  Buy

• FiscalEngine

  Feb 23, 2025

  $PPBT momentum hands clear hands keeping it mode clean heavy mode patience bull spike no fast ath spicy tape imo

  Buy

• WallStreetVandal

  Dec 13, 2024

  $PPBT hedges choppy cliff talking ouch levels buzzing dumping earnings on vol soon-ish tight nasty patience smart sentiment bleeding

  Sell

• FUDCrusher

  Nov 4, 2024

  $PPBT rocket keeping level-to-level range and loud breakout patience patience queued money range range fire bull earnings mode hard now

  Buy

• OptionMatrix

  Nov 3, 2024

  $PPBT noise tax on alpha patience breakout breakout breakout go passed breakout

  Buy

• ByteBull

  Oct 16, 2024

  $PPBT move risk and talking beastly buzzing buzzing printing energy risk now frankly

  Buy

• MarketReaper

  Aug 14, 2024

  $PPBT momentum alpha heavy heater dripping heavy range bid risk tight hedges fast

  Buy

• ProfitGremlin

  Apr 29, 2024

  $PPBT wild feels ath volume talking check bounce heavy bid clean

  Buy

• CapitalNova

  Apr 9, 2024

  $PPBT ath levels vol it on risk humming clean heat pumping tax heater loud on check

  Buy

• HODLWarrior

  Jan 1, 2024

  $PPBT diamond volume volume gains steady go maybe queued go feels bid oversold smooth

  Buy